Xenon Pharmaceuticals XENE Net proceeds from sales of subsidiary shares
Net proceeds from sales of subsidiary shares at other companies
Other financials
Where this comes from
Reported directly by Xenon Pharmaceuticals in its filing.
Tagged under the XBRL concept us-gaap:ProceedsFromIssuanceInitialPublicOffering.
The official record: Xenon Pharmaceuticals’s 10-K, filed February 27, 2025, on SEC EDGAR. View the filing →
Ask your AI about Xenon Pharmaceuticals's net proceeds from sales of subsidiary shares.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is Xenon Pharmaceuticals's net proceeds from sales of subsidiary shares?
- Xenon Pharmaceuticals (XENE) reported net proceeds from sales of subsidiary shares of $3.02M in Q4 2024.
- How has Xenon Pharmaceuticals's net proceeds from sales of subsidiary shares changed year-over-year?
- Xenon Pharmaceuticals's net proceeds from sales of subsidiary shares decreased by 96.6% year-over-year, from $88.37M to $3.02M.
- What is the long-term trend for Xenon Pharmaceuticals's net proceeds from sales of subsidiary shares?
- Over 2 years (2022 to 2024), Xenon Pharmaceuticals's net proceeds from sales of subsidiary shares has grown at a -79.1% compound annual growth rate (CAGR), from $277.77M to $12.08M.